New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Tumor bulk-RNA seq identifies patients at high risk of progression in non-complete pathological responders

Tumor bulk-RNA seq identifies patients at high risk of progression in non-complete pathological responders

by International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public DomainResearchers from Spain have identified an immune expression signature in surgical specimens associated with d
World medicine December 15,2023
Tumor bulk-RNA seq identifies patients at high risk of progression in non-complete pathological responders

Tumor bulk-RNA seq identifies patients at high risk of progression in non-complete pathological responders

by International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public DomainResearchers from Spain have identified an immune expression signature in surgical specimens associated with d
World medicine December 15,2023
A new microfluidic system could keep tabs on cancer treatment

A new microfluidic system could keep tabs on cancer treatment

by Catherine Graham,Johns Hopkins UniversityOverview of workflow for assessing drug response from cancer cells. (a) Schematic workflow for directly assaying diseased cells from patient liquid bi
World medicine December 15,2023
A new microfluidic system could keep tabs on cancer treatment

A new microfluidic system could keep tabs on cancer treatment

by Catherine Graham,Johns Hopkins UniversityOverview of workflow for assessing drug response from cancer cells. (a) Schematic workflow for directly assaying diseased cells from patient liquid bi
World medicine December 15,2023
Inverse relationship found between cancer diagnosis and Alzheimer's disease

Inverse relationship found between cancer diagnosis and Alzheimer's disease

by Hannah Echols,University of Alabama at BirminghamCredit: Pixabay/CC0 Public DomainWith increased age comes the increased risk to develop cancer or dementia. Both conditions share similar risk
World medicine December 15,2023
Inverse relationship found between cancer diagnosis and Alzheimer's disease

Inverse relationship found between cancer diagnosis and Alzheimer's disease

by Hannah Echols,University of Alabama at BirminghamCredit: Pixabay/CC0 Public DomainWith increased age comes the increased risk to develop cancer or dementia. Both conditions share similar risk
World medicine December 15,2023
Big data and AI meet cancer research

Big data and AI meet cancer research

by Michele W. Sequeira, University of New Mexico Comprehensive Cancer CenterIdentification of immune–metabolic regulators. A, Overall schematic of regulation and immune modules of BipotentR. The regul
World medicine December 15,2023
Big data and AI meet cancer research

Big data and AI meet cancer research

by Michele W. Sequeira, University of New Mexico Comprehensive Cancer CenterIdentification of immune–metabolic regulators. A, Overall schematic of regulation and immune modules of BipotentR. The regul
World medicine December 15,2023
Awakening dormant cells to fight cancer

Awakening dormant cells to fight cancer

byUniversity of GenevaTargeted inhibition of the DAPKs (Death-associated protein kinase 1 and 3) reduces the proportion of slow-proliferating/senescent-like HuRLow cells and the adaptive respons
World medicine December 15,2023
Awakening dormant cells to fight cancer

Awakening dormant cells to fight cancer

byUniversity of GenevaTargeted inhibition of the DAPKs (Death-associated protein kinase 1 and 3) reduces the proportion of slow-proliferating/senescent-like HuRLow cells and the adaptive respons
World medicine December 15,2023
3D model of brain tumor environment could aid personalized treatment

3D model of brain tumor environment could aid personalized treatment

byVirginia TechGabriela Mendes, a postdoctoral associate at Fralin Biomedical Research Institute at VTC, holds an example of the 3D model of the glioblastoma tumor microenvironment the lab devel
World medicine December 15,2023
3D model of brain tumor environment could aid personalized treatment

3D model of brain tumor environment could aid personalized treatment

byVirginia TechGabriela Mendes, a postdoctoral associate at Fralin Biomedical Research Institute at VTC, holds an example of the 3D model of the glioblastoma tumor microenvironment the lab devel
World medicine December 15,2023
Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

byNational Cancer InstituteLeft frame: Normally, tumor cells (purple) evade the immune system's T cells (pink) by expressing a checkpoint protein known as PD-L1. Right frame: Atezolizumab (T
World medicine December 15,2023
Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

byNational Cancer InstituteLeft frame: Normally, tumor cells (purple) evade the immune system's T cells (pink) by expressing a checkpoint protein known as PD-L1. Right frame: Atezolizumab (T
World medicine December 15,2023
NADIM II trial provides support for neoadjuvant chemoimmunotherapy for patients with non-small cell lung cancer

NADIM II trial provides support for neoadjuvant chemoimmunotherapy for patients with non-small cell lung cancer

by International Association for the Study of Lung CancerDr. Mariano Provencio, Hospital Universitario Puerta de Hierro-Majadahonda, Spain. Credit: Dr. Mariano Provencio, Hospital Universitario Puerta
World medicine December 15,2023
NADIM II trial provides support for neoadjuvant chemoimmunotherapy for patients with non-small cell lung cancer

NADIM II trial provides support for neoadjuvant chemoimmunotherapy for patients with non-small cell lung cancer

by International Association for the Study of Lung CancerDr. Mariano Provencio, Hospital Universitario Puerta de Hierro-Majadahonda, Spain. Credit: Dr. Mariano Provencio, Hospital Universitario Puerta
World medicine December 15,2023
Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention

Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention

by Impact Journals LLCEffect of exercise intervention on survey indices of depressive symptoms (A), activity (B), and physical disability (C) during the baseline (B), intervention (I), and post-interv
World medicine December 15,2023
Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention

Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention

by Impact Journals LLCEffect of exercise intervention on survey indices of depressive symptoms (A), activity (B), and physical disability (C) during the baseline (B), intervention (I), and post-interv
World medicine December 15,2023
Breast cancer: New drug shrinks brain metastases

Breast cancer: New drug shrinks brain metastases

by Johannes Angerer,Medical University of ViennaWaterfall plot of responses in patients evaluable for response by RANO-BM criteria in the TUXEDO-1 trial. Blue bars illustrate the radiographic ch
World medicine December 15,2023
Breast cancer: New drug shrinks brain metastases

Breast cancer: New drug shrinks brain metastases

by Johannes Angerer,Medical University of ViennaWaterfall plot of responses in patients evaluable for response by RANO-BM criteria in the TUXEDO-1 trial. Blue bars illustrate the radiographic ch
World medicine December 15,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com